RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
- Status
- COMPLETED
- Phase
- PHASE3
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide Maintenance Post-debulking in Advanced CTCL
- Status
- TERMINATED
- Phase
- PHASE3
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
- Status
- COMPLETED
- Phase
- PHASE3
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide and High-Dose Melphalan
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2